Company news

X4 Pharmaceuticals, Inc. news in 2026

X4 Pharmaceuticals, Inc.'s news releases, calls and decks from 2026, newest first.

View company

X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update

November 4, 2026

X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026

November 3, 2026

X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day

October 29, 2026

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

October 9, 2026

X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures

October 8, 2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2026

X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference

September 9, 2026

X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting

September 8, 2026

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 6, 2026

X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors

July 1, 2026

X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 26, 2026

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 6, 2026

X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union

April 29, 2026

X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

March 17, 2026

X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference

March 4, 2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 2, 2026

X4 Pharmaceuticals Receives Positive Opinion from the EMA CHMP Recommending Approval of Mavorixafor in the EU for WHIM Syndrome

February 26, 2026

X4 Pharmaceuticals to Participate in Guggenheim’s Emerging Outlook: Biotech Summit 2026

February 3, 2026

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 2, 2026

Decks in 2026